Editas Medicine, Inc. (EDIT)

5,32 +0,10 (+1,92%) Börsenschluss: 04:00PM EDT

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000
https://www.editasmedicine.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 265

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Gilmore O'Neill M.D.	President, CEO & Director	1,04M	N/A	1964
Mr. Erick J. Lucera C.F.A., CPA	CFO & Executive VP	911,46k	N/A	1968
Dr. Linda C. Burkly Ph.D.	Executive VP & Chief Scientific Officer	522,44k	N/A	1957
Dr. Baisong Mei M.D., Ph.D.	Executive VP & Chief Medical Officer	654,9k	N/A	1964
Dr. Feng Zhang Ph.D.	Co-Founder & Scientific Advisory Board Member	N/A	N/A	N/A
Dr. George McDonald Church Ph.D.	Co-Founder & Scientific Advisory Board Member	N/A	N/A	1954
Cristi Barnett	Corporate Communications & Investor Relations	N/A	N/A	N/A
Ms. Charlene Stern J.D., Ph.D.	Executive VP & General Counsel	N/A	N/A	N/A
Ms. Linea Aspesi	Executive VP & Chief People Officer	N/A	N/A	1970
Ms. Caren Deardorf	Executive VP and Chief Commercial & Strategy Officer	N/A	N/A	1966

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Corporate Governance

Editas Medicine, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 6. Die grundlegenden Scores sind Audit: 2, Vorstand: 4, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.